← Back to patent-cliff list
AT-004(Arctic Therapeutics)
Tier C — Watch / tradeAT-004(Arctic Therapeutics)
Arctic Therapeutics International
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AChE
Indications (approved)：Acne vulgaris, Rosacea, Atopic dermatitis, Psoriasis
Regional status
US
-
EU
Phase II
2023-11-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of AT-004(Arctic Therapeutics)?
Approved indications include: Acne vulgaris, Rosacea, Atopic dermatitis, Psoriasis.
When does the AT-004(Arctic Therapeutics) patent expire?
No public expiry year is available for AT-004(Arctic Therapeutics) yet; this page updates once verified.
How do I get a quote for AT-004(Arctic Therapeutics) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02